Generare secures €20M to scale molecular discovery platform

Generare, a Paris-based biotechnology company focused on generating molecular data for drug development, has raised €20 million in a Series A funding round. The round was co-led by Alven and Daphni, with participation from existing investors including Galion.exe, Teampact Ventures, and VIVES Partners.

Drug discovery has historically been constrained to a relatively narrow chemical space, largely due to limited data availability beyond it. At the same time, microbial genomes contain a vast reservoir of molecular diversity developed over billions of years, much of which remains unexplored. Generare is focused on generating and characterising this previously inaccessible data at scale to make it usable for drug development.

Founded in 2023 by Guillaume Vandenesch and Vincent Libis, the company is building a large-scale dataset of novel small molecules derived from microbial genomes. By decoding previously unexplored biological data, it aims to expand the chemical space available for drug discovery and address long-standing limitations in access to high-quality molecular data.

The company specialises in small molecules, the class of compounds behind many widely used medicines, with each newly identified molecule contributing to an expanding dataset. Its platform combines high-throughput cloning and sequencing technologies to identify, express, and characterise bioactive compounds, generating structured data on their properties and potential therapeutic applications.

According to co-founder and CEO Vandenesch, the lack of novel, high-quality molecular data remains a key constraint in drug discovery, limiting the effectiveness of existing approaches and models.

Generare reports increasing adoption of its platform among pharmaceutical and research organisations, with newly identified molecules being used in early-stage drug development. The company is focused on scaling its dataset and expanding its capabilities to meet growing demand.

The funding will be used to expand the company’s compound library, scale its discovery platform, and grow its multidisciplinary team as it continues to develop its data-driven approach to drug discovery.